I think that ideally it would be more advantageous if that partner Was in the biotech field, not sure what non biotech entity could take this up, any ideas?
Biotech partner would have the advantage of established network, distribution and marketing in place in this field, looking at it from a layman’s point of view but it does seem to make sense until I am enlightened otherwise.
I think that ideally it would be more advantageous if that...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.65 |
Change
-0.060(0.38%) |
Mkt cap ! $300.8M | |||
| Open | High | Low | Value | Volume |
| $15.72 | $15.85 | $15.51 | $1.660M | 117.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 312 | $15.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.65 | 626 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |